PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NONHODGKIN LYMPHOMA (NHL)

069

  • Younes, A.
  • Flinn, I.
  • Berdeja, J.
  • Friedberg, J.
  • Alberti, S.
  • Thieblemont, C.
  • Morschhauser, F.
  • Hellemans, P.
  • Hall, B.
  • Smit, J.
  • Skee, D.
  • de Vries, R.
  • Todorovic, M.
  • Khan, I.
  • Fourneau, N.
  • Oki, Y.

  • 1MD Anderson Cancer Center, The University of Texas, Houston, TX, USA;

    2Centennial Medical Center, Sarah Cannon Research Institute, Nashville, USA;

    3Tennessee Oncology, Sarah Cannon Research Institute, Nashville, USA;

    4Wilmot Cancer Center, University of Rochester Medical Center, Rochester, USA;

    5Service Hemato-oncologie, APHP-Hopital Saint Louis, Paris, France;

    6Service Maladies du Sang, CHRU de Lille, Hopital Claude Huriez, Lille, France;

    7Janssen Research and Development, LLC, Beerse, Belgium;

    8Janssen Research and Development, LLC, Spring House, PA, USA;

    9Janssen Research and Development, LLC, Raritan, NJ, USA;

    10Janssen Research and Development, LLC, Belgrade, Serbia and Montenegro.

Hematological Oncology 31:p 119-120, June 2013.
Copyright © 2013 John Wiley & Sons, Inc.